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Case Report
Introduction
Wilson disease (WD) is an autosomal recessive disorder 
with a prevalence traditionally reported of 1 in 30,000 
individuals,1,2 but more recent studies indicate that it could 
affect 1 in 7,026 individuals.3,4 The underlying genetic defect 
is based on disease-causing mutations in the ATP7B gene,5 
which encodes a copper transporting adenosine triphospha-
tase crucial for biliary copper excretion as well as synthesis 
and maturation of functional ceruloplasmin.6,7 Absent or 
reduced function of this protein results in copper accumula-
tion within multiple organs, most notably the liver, brain, and 
cornea. While patients may present with a variety of symp-
toms, the clinical manifestations of WD are predominately 
hepatic, neurologic, and psychiatric. There are limited medi-
cal treatment options for WD that have shown to prevent 
sequelae of the disease and little research has been done to 
determine the most effective way to transition between 
agents in the event of ineffective therapy or a patient’s inabil-
ity to tolerate the medication.
Case Presentation
The patient was first diagnosed with WD at age 32, when he 
presented with elevated liver enzymes and workup revealing 
low ceruloplasmin. He started to be followed at University of 
California Davis Hepatology Clinic when he was 56 years 
old. His comorbidities include well-controlled HIV on efavi-
renz/emtricitabine/tenofovir.
At the time of establishing care at University of California 
Davis in 2006, he had compensated cirrhosis with elevated 
liver enzymes and mild hepatomegaly. He underwent liver 
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Abstract
Background. Available treatments for Wilson disease (WD) prevent longterm complications of copper accumulation. 
Current anti-copper agents include zinc salts, penicillamine, and trientine. Patients with WD may switch between the 
agents for a number of reasons. Due to the different mechanisms of action between the copper chelators and zinc salts, 
transitioning could require a period of overlap and increased monitoring. There are no large studies that investigate the 
best transition strategies between agents. In this article, we review the treatments for WD and how to monitor for 
treatment efficacy. Case Summary. The patient had been diagnosed with WD for over 20 years prior to establishing care in 
our Hepatology Clinic. During his initial course, he was transitioned from penicillamine to zinc due to evidence suggesting 
penicillamine had greater adverse effects in the long term. Later, he was switched to trientine. His liver enzymes and 24-
hour urine copper were monitored. During these years, he intermittently had some financial hardship, requiring him to 
be on penicillamine rather than trientine. He also had developed acute kidney injury. Overall, his liver disease remained 
under control and he never had signs of decompensated cirrhosis, but had fluctuations of liver enzymes over the years. 
Conclusion. Anti-copper treatment for WD has to be tailored to medication side effects profile, patient’s chronic and 
emerging comorbidities, as well as costs. Transitioning regimens is often challenging, and it requires closer monitoring, 
with no predictors of response.
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biopsy, which demonstrated moderate portal and lobular 
lymphocytic infiltrate, periportal and focal bridging fibrosis 
(stage 2-3), and moderate steatosis (25%). Drug-induced 
liver injury was considered, especially with ongoing highly 
active antiretroviral therapy, as approximately 20% of all 
patients on highly active antiretroviral therapy have liver 
enzymes abnormalities.8 Other causes of elevated liver 
enzymes including alcohol abuse, viral hepatitis, autoim-
mune hepatitis, α-1 antitrypsin deficiency, and hemochro-
matosis were excluded. He had been on penicillamine (PCA) 
250 mg 3 times daily for more than 20 years, and his HIV 
was under control as shown by CD4 count 543 cells/mm3 
and viral load <50 copies/mL. His past medical history 
includes nephrolithiasis, major depressive disorder, hyper-
tension, and type 2 diabetes.
On physical examination, the patient had no scleral icterus. 
Abdomen nondistended, liver palpable at about 1 cm under 
the right costal margin with sharp edge. No collateral veins, 
ascites, peripheral edema, flapping tremor, signs of encepha-
lopathy, and spider angiomata. No focal neurologic deficits 
on physical examination, cranial nerves intact, alert, and ori-
ented to person, place, time, and situation.
Laboratory
Negative serology for hepatitis B (positive HBsAb) and C. 
chemistry panel showed normal electrolytes and kidney 
function (sodium 145 mEq/L, potassium 4.1 mEq/L, chlo-
ride 105 mEq/L, bicarbonate 26 mEq/L, blood urea nitrogen 
11 mg/dL, creatinine 0.6 mg/dL, and calcium 9.4 mg/dL). 
Bilirubin levels were 0.7 mg/dL, alkaline phosphatase 
96 IU/L, aspartate transaminase 54 IU/L, and alanine trans-
aminase 84 IU/L. Blood count was within normal limits 
including normal platelets.
Imaging
Ultrasound of abdomen demonstrated hepatomegaly with 
moderate degree of hepatosteatosis with evidence of portal 
hypertension with splenomegaly, and no ascites. Magnetic 
resonance imaging of brain demonstrated mild cerebral cor-
tical volume loss. There was no evidence of alterations in the 
striatum or in the white matter.
Final Diagnosis, Treatment, Outcome, 
and Follow-up
The patient was compliant on PCA for more than 20 years 
when he established care in 2007, but his transaminases 
were persistently elevated. Compliance was confirmed by 
24-hour urinary copper levels in 300 to 400 µg range. Given 
growing evidence that PCA treatment is affected by several 
long-term side effects,9 including nephrotoxicity with protein-
uria and hematuria, skin progeric changes, and autoimmune 
conditions,10 he was switched over to zinc acetate shortly 
after establishing care.6
In July 2010, given persistent elevation of liver enzymes 
(aspartate transaminase 55-90 IU/L, alanine transaminase 
36-55 IU/L) and new published evidence that chelation treat-
ment had lower rates of treatment failure and orthotopic liver 
transplantation, he was switched to trientine (Table 1).9 From 
2011 to 2014, dose adjustments to trientine were made 
(Figures 1 and 2) mainly due to development of mild normo-
cytic anemia, hemoglobin of 11.5 g/dL from baseline of 15 g/
dL, with mean corpuscular volume of 89 fL. This was attrib-
uted to overtreatment with trientine as other causes of ane-
mia were excluded, and there were no changes to HIV 
medications. In 2015, he eventually had to stop trientine due 
to lack of insurance coverage and was switched to PCA.
In February 2017, he developed acute kidney injury (ele-
vation in baseline creatinine from 0.84 to 1.34 mg/dL) fol-
lowing a unilateral renal stone, for which he underwent 
cystoscopy with laser lithotripsy and stent placement. He 
was also noted to have proteinuria 50 mg/dL following this 
incident, so in an attempt to minimize contributing nephro-
toxic agents, he was switched off of PCA to trientine. His 
antiretroviral therapy for HIV was also changed from efavi-
renz/emtricitabine/tenofovir to emtricitabine/rilpivirine/
tenofovir alafenamide. As a result, his creatinine down-
trended to baseline by June 2017. Liver enzymes were stable 
during this time with no acute rises.
In March 2018, new financial issues prevented him to 
continue with the full dose of copper chelating agent. At that 
point, zinc acetate was added to trientine. In October 2018, 
he was back on trientine alone again as he obtained full 
insurance coverage while transaminases remained normal.
Discussion
Therapies for WD include chelating agents, PCA, and tri-
entine, which increase urinary copper excretion and zinc 
salts that inhibit intestinal copper absorption. The goal of 
initial treatment of WD is to reestablish copper balance, 
whereas the maintenance phase serves to maintain these 
levels without inducing copper deficiency.6 Maintenance 
represents lifelong therapy, unless a patient undergoes 
liver transplant.11 However, despite its side effects and 
limitations, current medical treatment for WD is effective 
in avoiding disease progression and liver transplant for the 
majority of patients provided treatment is tailored and 
optimized to the patient’s needs and comorbidities. In par-
ticular, we are not aware of case reports describing WD 
treatment options and outcomes in patients with HIV. 
Therefore, connections between the available literature 
and the current case may appear marginal and based on the 
treating clinician experience and assessment.
Penicillamine was among the first oral agents introduced for 
treating WD.12 Although multiple studies have demonstrated 
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its efficacy in treatment of WD,13-16 PCA has an extensive 
side effect profile. Patients can experience early hypersensi-
tivity reactions within 1 to 3 weeks of initiation of treatment, 
characterized by fever, cutaneous eruptions, cytopenias, and 
proteinuria. Late-onset reactions, although rare, may be fatal 
and include drug-induced lupus, nephrotic syndrome leading to 
renal failure, severe thrombocytopenia, or aplastic anemia.13,17-19 
In the event of a severe reaction, PCA should be discontinued 
and patient should be transitioned to alternative therapy.19 
PCA should be avoided in patients with a penicillin allergy, 
Table 1. Transitioning Between Therapeutic Agents in Wilson Diseasea.
When to Transition How to Transition Monitoring
PCA to 
trientine
•• Patient unable to tolerate 
PCA
•• Development of nephrotic 
syndrome, severe 
thrombocytopenia, or 
aplastic anemia
No taper or overlap indicated Baseline CBC, CMP, and 24-hour urinary copper 
prior to switch
Repeat above laboratory tests monthly for 3 to 
4 months
Goal: Maintain 24-hour urinary copper 200 to 
500 µg, stable ALT
Long-term: Repeat blood tests, including CBC 
and CMP, and 24-hour urinary copper at 
least every 6 months; 24-hour urinary copper 
should be in the 200 to 500 µg/day range
PCA to 
zinc salts
•• Patient unable to tolerate 
PCA
•• Development of 
renal failure, severe 
thrombocytopenia/aplastic 
anemia
•• Worsening neurologic 
symptoms
•• Pregnancy
Start zinc at 50 mg TID, uptitrate by 50 
mg increments as necessary
Continue PCA for at least 3 months 
after initiating zinc therapy
PCA and zinc dosing must be spread 
out so that they are not taken at the 
same time; PCA cannot be given at 
meal times
CMP, 24-hour urinary copper prior to switch 
and every 3 months until urinary copper at 
goal/stabilizes
Goal: Maintain urinary copper <75 µg, stable 
liver enzymes
Long-term: Repeat blood tests, including CBC 
and CMP, and 24-hour urinary copper at 
least every 6 months; 24-hour urinary copper 
should be <75 µg/day
Trientine 
to zinc 
salts
•• Financial limitations
•• Limited drug availability
•• Development of pancolitis
•• Pregnancy
Start zinc at 50 mg TID, titrate by 50 
mg increments as necessary; when 
starting zinc, reduce trientine dose by 
250 mg and reduce by 250 mg every 
month until termination of trientine
Continue trientine for at least 3 
months after initiating zinc therapy
Trientine and zinc dosing must be 
spread out so that they are not taken 
at the same time; PCA cannot be 
given at meal times
CMP, 24-hour urinary copper prior to switch 
and every 3 months until urinary copper at 
goal/stabilizes
Goal: Maintain urinary copper <75 µg, stable 
liver enzymes
Long-term: repeat blood tests, including CBC 
and CMP, and 24-hour urinary copper at 
least every 6 months; 24-hour urinary copper 
should be <75 µg/day
Zinc 
salts to 
trientine
•• Ineffective therapy 
demonstrated by 
uptrending liver enzymes, 
development of liver 
synthetic dysfunction
No taper or overlap indicated Baseline CBC, CMP, and 24-hour urinary copper 
prior to switch
Repeat above laboratory tests monthly for 3 to 
4 months
Goal: Maintain urinary copper 200 to 500 µg, 
stable liver enzymes
Trientine 
or zinc 
salts to 
PCA
•• Financial limitations
•• Patient’s preference
No taper or overlap indicated Baseline CBC, CMP, and 24-hour urinary copper 
prior to switch
Repeat above laboratory tests monthly for 1 to 
2 months
Goal: Maintain urinary copper 200 to 500 µg, 
stable liver enzymes
Long-term: Repeat blood tests, including CBC 
and CMP, and 24-hour urinary copper at 
least every 6 months; 24-hour urinary copper 
should be in the 200 to 500 µg/day range
Repeat UA every 6 months to check on 
proteinuria
Abbreviations: PCA, penicillamine; CBC, complete blood count; CMP, complete metabolic panel (including liver enzymes); ALT, alanine transaminase;  
TID, 3 times a day; UA, urinalysis.
aDose of zinc refers to elemental zinc.
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history of PCA-related aplastic anemia or agranulocytosis, or 
renal disease. When possible, it should also be avoided in 
patients with neuropsychiatric manifestations of WD, as at least 
10% of those treated have had worsening of symptoms.8,20-22 
In the described case, the rationale for initially switching 
from PCA to zinc acetate was the concern about emerging 
of autoimmune conditions and nephropathy in a patient 
with multiple comorbidities and on lifelong pharmacologi-
cal treatment.
Trientine was developed as a therapeutic option for 
patients who were unable to tolerate or had contraindications 
to PCA. It has been shown to be as effective for treatment of 
WD and associated with fewer side effects compared with 
PCA.23-26 Although hypersensitivity reactions and pancyto-
penia can occur with trientine, these side effects are rare and 
can often be addressed with dose reduction and use of ste-
roids. While worsening of neuropsychiatric symptoms has 
also been noted with trientine use, its incidence is lower.6,18,27 
Figure 1. ALT and AST levels trends.
Abbreviations: ALT, alanine transaminase; AST, aspartate transaminase; BID, 2 times a day; TID, 3 times a day; QID, 4 times a day.
Figure 2. Twenty-four-hour urine copper trends.
Abbreviations: BID, 2 times a day; TID, 3 times a day; QID, 4 times a day.
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Rare side effects of trientine include sideroblastic anemia, 
pancolitis, and hemorrhagic gastritis. Notably, a large barrier 
to use of trientine therapy is availability or cost of the drug, 
as seen in our patient described above.
The main advantage of zinc salts over chelating agents is 
that they are generally well tolerated by patients due to fewer 
side effects. Gastric irritation is the most commonly described 
side effect, though that may be due to the salt preparation 
rather than zinc itself. Unlike the chelating agents, zinc can 
also be safely given during pregnancy without dose reduc-
tion. Zinc has been shown to be effective in controlling cop-
per levels during maintenance therapy,15,28-30 though in some 
studies, chelators have been shown to be better at slowing 
progression of WD if tolerated.9,31 In our patient, despite 
compliance with zinc therapy, he had rising liver function 
tests, suggesting ineffective maintenance therapy with zinc. 
It has also been suggested that zinc may be as effective as 
chelators as initial therapy,15,32-34 especially in patients 
who are unable to tolerate chelating agents, who have sig-
nificant neuropsychiatric disease, or in patients who are 
presymptomatic.
Regardless of therapy selection, patients must be closely 
monitored clinically and with routine laboratory tests while 
on therapy. With initiation of treatment or modification of 
regimen, patients should be monitored at least every 3 
months for efficacy of treatment, compliance, and potential 
therapy adverse effects. In addition to clinical evaluation, 
recommended laboratory tests included liver enzymes, inter-
national normalized ratio, complete blood count, urinalysis, 
and surrogates of copper metabolism, including serum-free 
copper, ceruloplasmin, and 24-hour urinary copper excre-
tion. Monitoring of urine copper may be the most effective 
way to evaluate compliance and success of therapy.6,35 When 
on chelating agents, elevated values of urine copper may 
suggest non-adherence and hepatic deterioration, whereas 
low values may indicate overtreatment when accompanied 
by low non–ceruloplasmin-bound copper.6,36 Conversely, if a 
patient is on zinc, marked reduction of urine copper repre-
sents reduction of total body copper, implying effective ther-
apy with zinc. Monitoring liver enzymes also provides 
insight into efficacy of therapy. Rising liver enzymes despite 
compliance to therapy may suggest ineffective treatment and 
the need to transition to an alternative agent.
While several studies have been done regarding the effi-
cacy of chelating agents13 and zinc, as well as comparing the 
various agents available for treatment of WD,14,15,34,37 there is 
little to no commentary on dose adjustments or the most 
effective way to transition between different agents if neces-
sary. As demonstrated by our patient above, patients may be 
transitioned between therapies for various reasons, whether 
it be inability to tolerate therapy due to adverse effects, inef-
fective treatment, comorbidities, or financial concerns. Since 
zinc typically requires 2 to 6 months of treatment during 
initial therapy to reach the maintenance phase, tapering 
is likely required when switching to zinc. Transitioning 
between agents is further complicated when on multiple 
agents due to timing of medications as absorption of chela-
tors is affected by meals.6,18 In addition, clinicians can pre-
scribe other agents including vitamin E, which may be 
beneficial given its antioxidant properties and some limited 
evidence of reduced levels of vitamin E in plasma of patients 
with WD.38 It is also noticeable that other treatment options 
may become soon available for the treatment of WD, and they 
include tetrathiomolybdate bis-choline39 and methanobactin.40 
An additional layer of complexity is related to the possible 
combination treatment. Even though most clinicians are con-
cerned about the binding of zinc by copper chelators if 
administered concomitantly, data from Askari at al41 showed 
that the combination treatment with trientine and zinc in case 
of decompensated cirrhosis is associated with significant 
improvement of liver function. As shown in Table 1, we are 
proposing specific recommendations for transitioning 
between different therapeutic agents.
In conclusion, although there have been studies explor-
ing the efficacy of various treatments for WD and compar-
ing these agents, there is limited research regarding effective 
transitions between these agents. We have proposed spe-
cific recommendations for transitioning between therapeu-
tic agents. However, further studies are warranted to help 
determine the optimal transition indications, timing, and 
monitoring.
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